Announcements Trials
Browse Landscape

Status

No longer available 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 59Expanded_access 4Observational 1

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Expanded_access × elotuzumab × Clear all
NCT02856438 2023-12-19

Early Patient Access Treatment Use Protocol CA204-220

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02368301 2023-11-30

Expanded Access Treatment Protocol CA204-143

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT03126617 2021-11-29

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Bristol-Myers Squibb

No longer available
Plasma cell

Multiple Myeloma

NCT02541643 2015-09-04

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

Icahn School of Medicine at Mount Sinai

No longer available
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡